Docket No.: 04393/0202300-US0 (PATENT)

Examiner: M. G. Leavitt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Kunihiro Ohta et al.

Application No.: 10/522,644 Confirmation No.: 7488

Filed: February 28, 2005 Art Unit: 1633

For: METHOD OF ENHANCING

HOMOLOGOUS RECOMBINATION OF SOMATIC CELLS AND METHOD OF CONSTRUCTING SPECIFIC ANTIBODY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Madam:

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed: (Check one of the boxes A-D)

A.	within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above identified national application
В.	before the mailing date of a first office action on the merits, or a first office action after filing a request for continued examination.
C.	after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary statement in box "i" below or paid the necessary fee in box "ii" below.
•	(check one of the boxes "i" and "ii" below:)
[i. Counsel states that, upon information and belief, each item of information listed herein was (check one of boxes (a) or (b))
	 (a) first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
	(b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
	x ii. Payment in the amount of the fee set forth in 1.17(p), presently \$180, is enclosed.
x D.	after (A), (B) and (C) above, but before payment of the issue fee: Applicant petitions under 37 C.F.R. $1.97(d)$ for the consideration of this IDS. Payment in the amount of the fee set forth in $1.17(p)$, presently \$180.00 is enclosed. Counsel certifies that, upon information and belief, each item of information listed herein was
	(check one of the boxes "a" and "b" below:)

Application No.: 10/522,644 Docket No.: 04393/0202300-US0

	An English translation of each document (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application , or English-language abstract (or claim) is enclosed.
	The requirement for a concise explanation of the relevance of any foreign language document is satisfied by the attached search report; citation of the documents cited in the search report shall not be construed as an admission that they are or are considered to be, material to patentability of the subject matter claimed herein (See MPEP §609).
	A concise explanation of the relevance of document(s) is set forth as follows: [Insert concise explanation of
	A concise explanation of the relevance of document(s) can be found on page(s) of the specification.
	A concise explanation of document(s) can be found on the attached sheet.
x 4.	No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 in the preamble to the final rules; 1135 OG 13 at 20).
x 5.	Other information being provided for the examiner's consideration follows:
	A European second Office Action, dated March 26, 2009, which issued during the prosecution of European Application No. 03771393.0 which corresponds to the present application.

6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in \$1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless other-wise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Early and favorable consideration is earnestly solicited.

Payment in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee due with this submission to Deposit Account No. 04-0100.

Dated: June 22, 2009

Respectfully submitted,

Shilpa V. Patel

Registration No.: 57,983 DARBY & DARBY P.C.

P.O. Box 770

Church Street Station

New York, New York 10008-0770

(212) 527-7700 (212) 527-7701 (Fax)

Attorneys/Agents For Applicant